RapidAI
CA - Menlo ParkBiotechnology
Focus: RapidAI develops CT and MRI blood flow visualization technology for neurological applications, operating as a Series C+ biotech focused on diagnostic imaging rather than traditional drug development.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Funding Stage
SERIES C +
Open Jobs
7+1 this month
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Should You Work at RapidAI?
AI assessmentRapidAI represents a high-risk, high-reward early-stage opportunity suitable only for candidates seeking exposure to emerging imaging technology and willing to accept pre-commercial execution risk.
Why Work Here
- Early-stage company (Series C+) with potential for significant equity upside if imaging platform gains clinical adoption
- Specialized focus on neurology and imaging technology offers deep technical expertise opportunity in high-growth diagnostic space
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for RapidAI
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.